|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
D'Andrilli G, Kumar C, Scambia G and
Giordano A: Cell cycle genes in ovarian cancer: Steps toward
earlier diagnosis and novel therapies. Clin Cancer Res.
10:8132–8141. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matei D: Novel agents in ovarian cancer.
Expert Opin Investig Drugs. 16:1227–1239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrandina G, Zannoni GF, Martinelli E,
Paglia A, Gallotta V, Mozzetti S, Scambia G and Ferlini C: Class
III beta-tubulin overexpression is a marker of poor clinical
outcome in advanced ovarian cancer patients. Clin Cancer Res.
12:2774–2779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bonelli P, Tuccillo FM, Borrelli A,
Schiattarella A and Buonaguro FM: CDK/CCN and CDKI alterations for
cancer prognosis and therapeutic predictivity. Biomed Res Int.
2014:3610202014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abukhdeir AM and Park BH: P21 and p27:
Roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10:e192008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Belletti B, Nicoloso MS, Schiappacassi M,
Chimienti E, Berton S, Lovat F, Colombatti A and Baldassarre G:
p27(kip1) functional regulation in human cancer: A potential target
for therapeutic designs. Curr Med Chem. 12:1589–1605. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vidal A and Koff A: Cell-cycle inhibitors:
Three families united by a common cause. Gene. 247:1–15. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang LW, Chao SL, Hwang JL and Chou YY:
Down-regulation of p27 is associated with malignant transformation
and aggressive phenotype of cervical neoplasms. Gynecol Oncol.
85:524–528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Paola F, Vecci AM, Granato AM, Liverani
M, Monti F, Innoceta AM, Gianni L, Saragoni L, Ricci M, Falcini F,
et al: p27/kip1 expression in normal epithelium, benign and
neoplastic breast lesions. J Pathol. 196:26–31. 2002. View Article : Google Scholar
|
|
12
|
Chu I, Sun J, Arnaout A, Kahn H, Hanna W,
Narod S, Sun P, Tan CK, Hengst L and Slingerland J: p27
phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell.
128:281–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmidt M and Fan Z: Protection against
chemotherapy-induced cytotoxicity by cyclin-dependent kinase
inhibitors (CKI) in CKI-responsive cells compared with
CKI-unresponsive cells. Oncogene. 20:6164–6171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xing H, Wang S, Hu K, Tao W, Li J, Gao Q,
Yang X, Weng D, Lu Y and Ma D: Effect of the cyclin-dependent
kinases inhibitor p27 on resistance of ovarian cancer multicellular
spheroids to anticancer chemotherapy. J Cancer Res Clin Oncol.
131:511–519. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le XF, Mao W, He G, Claret FX, Xia W,
Ahmed AA, Hung MC, Siddik ZH and Bast RC Jr: The role of p27(Kip1)
in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian
cancer cells. J Natl Cancer Inst. 103:1403–1422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pohl PC, Carvalho DD, Daffre S, Vaz Ida S
Jr and Masuda A: In vitro establishment of ivermectin-resistant
rhipicephalus microplus cell line and the contribution of ABC
transporters on the resistance mechanism. Vet Parasitol.
204:316–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Hershko DD: Cyclin-dependent kinase
inhibitor p27 as a prognostic biomarker and potential cancer
therapeutic target. Future Oncol. 6:1837–1847. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis
of DNA methylation and gene expression reveals specific signaling
pathways associated with platinum resistance in ovarian cancer. BMC
Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ling Y, Zhang C, Xu Y, Zhu J, Zhu C, Lu M,
Liu Y and Zhou T: Promoter methylation-associated silencing of
p27kip1 gene with metastasis in esophageal squamous cell carcinoma.
Mol Med Rep. 9:1075–1079. 2014.PubMed/NCBI
|
|
21
|
Qian X, Jin L, Kulig E and Lloyd RV: DNA
methylation regulates p27kip1 expression in rodent pituitary cell
lines. Am J Pathol. 153:1475–1482. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li G, Ji Y, Liu C, Li J and Zhou Y:
Reduced levels of p15INK4b, p16INK4a, p21cip1 and p27kip1 in
pancreatic carcinoma. Mol Med Rep. 5:1106–1110. 2012.PubMed/NCBI
|
|
23
|
Stanganelli C, Arbelbide J, Fantl DB,
Corrado C and Slavutsky I: DNA methylation analysis of tumor
suppressor genes in monoclonal gammopathy of undetermined
significance. Ann Hematol. 89:191–199. 2010. View Article : Google Scholar
|
|
24
|
Horwitz SB: Taxol (paclitaxel): Mechanisms
of action. Ann Oncol. 5(Suppl 6): S3–S6. 1994.PubMed/NCBI
|
|
25
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Branch P, Masson M, Aquilina G, Bignami M
and Karran P: Spontaneous development of drug resistance: Mismatch
repair and p53 defects in resistance to cisplatin in human tumor
cells. Oncogene. 19:3138–3145. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mekhail TM and Markman M: Paclitaxel in
cancer therapy. Expert Opin Pharmacother. 3:755–766. 2002.
View Article : Google Scholar : PubMed/NCBI
|
